VRCA Q4 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$344,000-82.7% YoY

Gross Profit

-$281,000-81.7% margin

Operating Income

-$11M-3316.9% margin

Net Income

-$16M-4709.9% margin

EPS (Diluted)

$-2.41

QoQ Revenue Growth

+119.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$756,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$64M

Stockholders' Equity

-$10M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$344,000	$2M	-82.7%
Gross Profit	-$281,000	-$19M	+98.5%
Operating Income	-$11M	-$23M	+50.7%
Net Income	-$16M	-$25M	+34.2%

Revenue Segments

Product

$315,00092%

Collaboration

$29,0008%